Vitrakvi (larotrectinib) recommended by the CHMP for approval in the EU.
larotrectinib
-
August 15, 2019
-
February 07, 2019
The new site-agnostic cancer medicine, Vitrakvi (larotrectinib), gets accelerated approval from the U.S. Food and Drug Administration (FDA).